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Abstract
Background: Development of proximal and distal colorectal cancers involve partly different
mechanisms associated with the microsatellite instability (MSI) and the chromosomal instability
(CIN) pathways. Colorectal cancers in patients under 50 years of age represent about 5% of the
total number of tumors and have been associated with an increased frequency of MSI tumors.
However, MSI and CIN may play different roles in the development of colon cancer and rectal
cancer, and we have specifically investigated their contribution to the development of rectal cancer
at young age.
Methods: Thirty rectal cancers diagnosed before the age of 50 were characterized for DNA-
ploidy, MSI, mutations of KRAS and CTNNB1 and immunohistochemical expression of p53, -catenin
and of the mismatch repair (MMR) proteins MLH1 and MSH2.
Results: DNA aneuploidy was detected in 21/30 tumors, KRAS mutations in 6 tumors, no
mutations of CTNNB1 were detected but immunohistochemical staining for -catenin showed
nuclear staining in 6 tumors, and immunohistochemical expression of p53 was detected in 18
tumors. MSI was detected in 3/30 tumors, all of which showed and immunohistochemical loss of
staining for the MMR protein MSH2, which strongly indicates a phenotype associated with
hereditary nonpolyposis colorectal cancer (HNPCC).
Conclusions: MSI occurs only in a small fraction of the tumors from young patients with rectal
cancer, but when present it strongly indicates an underlying HNPCC-causing mutation, and other
mechanisms than HNPCC thus cause rectal cancer in the majority of young patients.
Background
Colorectal cancer represents 12% of the cancer cases in
Sweden with about 5% of the patients being below 50
years of age [1]. Rectal cancer constitutes about 1/3 of the
large bowel cancers and 5% of the patients are younger
than 50 years of age at diagnosis. Tumor development at
young age may be an indicator of hereditary cancer, such
as hereditary nonpolyposis colorectal cancer (HNPCC),
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cer at a mean age of 43 years and an increased risk also for
cancer of the endometrium, ovaries, urothelium and the
small intestine [2]. HNPCC has in population-based stud-
ies been demonstrated to account for about 2% of color-
ectal cancer, but has been estimated to cause about 1/3 of
the colorectal cancer cases occurring at young age [3,4].
HNPCC is caused by germline mutations in one of several
mismatch-repair (MMR) genes, most commonly in the
genes MLH1 and MSH2. Studies of colorectal cancers
from young patients have revealed MSI frequencies be-
tween 17 and 58% (compared to about 15% in sporadic
colorectal cancer), with the higher frequencies found in
patients below age 35 at diagnosis [5–10].
Colorectal cancer cells evade growth control through a se-
ries of genetic changes, which have been recognized to af-
fect distinctive pathways. The chromosomal instability
(CIN) pathway is involved in about 70–80% of the tu-
mors and is characterized by aneuploidy, multiple chro-
mosomal rearrangements, and an accumulation of
somatic mutations in oncogenes such as KRAS and -cat-
enin and tumor suppressor genes such as TP53 and the ad-
enomatous polyposis coli (APC) gene [11]. The
microsatellite instability (MSI) pathway characterizes
about 15% of the colorectal cancers and is associated with
diploid or near-diploid tumors and a defective MMR ma-
chinery, which is reflected as MSI in the tumor tissue. MSI
tumors are more likely to be right-sided with mucinous
histology, poor differentiation and tumor-infiltrating
lymphocytes [12]. MSI is only infrequently caused by
germline HNPCC-causing MMR gene mutations, but is
more commonly due to somatic hypermethylation of the
MLH1 promoter [13].
Differences in aetiology, clinical behaviour and histopa-
thology between colon cancer and rectal cancer suggest
different preferred tumorigenic pathways in these tumor
types. The few molecular genetic studies that have sepa-
rately analyzed these clinical entities demonstrate a lower
frequency of MSI and KRAS mutations and a higher fre-
quency of aneuploid tumors, p53 mutation/overexpres-
sion and -catenin overexpression in rectal cancer. These
findings are likely to reflect that CIN and the TP53 path-
ways contribute more than MSI to rectal cancer develop-
ment [3,14–18]. However, the importance of MSI versus
CIN in rectal cancer development in young patients has to
our knowledge not been characterized. We have therefore
studied 30 rectal cancers from patients below 50 years of
age, an age limit chosen in accordance with the Amster-
dam criteria for the classification of HNPCC [2] with re-
spect to flow cytometric DNA content, MSI, KRAS
mutations and immunohistochemical expression of the
MMR proteins MLH1 and MSH2 and the tumor suppres-
sor proteins p53 and -catenin. The aim was to clarify pos-
sible differences between colon cancer and rectal cancer in
young patients as regards the contribution of the MSI and
the CIN pathways to tumor formation and to estimate the
proportion of cases attributable to defective MMR.
Methods
Patients
Thirty patients diagnosed with histologically verified ade-
nocarcinomas of the rectum before age 50 were recruited
for the study (Table 1). Tumor stage was Dukes' A in 6 pa-
tients, B in 6, C in 12 and D in 6 patients. Tumor location
was low (<5 cm from the anal verge) in 5 patients, middle
rectum (5–10 cm) in 13, and high (10–15 cm) in 12 pa-
tients. Tumor histopathology was reviewed by a gastroin-
testinal pathologist (B.H.) and differentiation was
classified as moderate in 23 tumors and mucinous /signet
ring cell in 5 tumors, as well differentiated in 1 tumor and
as poor in 1 tumor. The patients had a mean age of 42
(range 25–49) years and the material included 9 women
and 21 men. Family histories of cancer were available
from 28 of the 30 patients; 20 had no history of familial
colorectal and/or endometrial cancer, 6 had one or more
relatives with colorectal and/or endometrial cancer at any
age and 2 patients fulfilled the Amsterdam II criteria for
the classification of HNPCC, whereas data on family his-
tory was not available from 2 patients (Table 1) [2]. Adju-
vant treatment with 5-fluorouracil (5-FU) and leucovorin
(in one case combined with oxaliplatin) was given to 16
patients. Median follow-up for the survivors was 46
(range 19–85) months. Six patients had metastasis at di-
agnosis and 9 patients died from tumor median 21 (range
3–40) months after diagnosis (Table 1). Paraffin embed-
ded tumor specimens were retrieved, and were sectioned
and stained with Hematoxylin & Eosin to verify that rep-
resentative tumor tissue was present in the sample. Three
10 M paraffin sections were used for DNA extraction (as
described below) and 3 M sections were used for immu-
nohistochemical staining. Permission for the study was
granted by the Lund university ethics committee.
DNA-extraction, PCR amplification and DNA sequencing
DNA was extracted from three 10-M sections of paraffin
embedded tumor tissue using proteinase-K incubation for
2–12 hours at 65C. After incubation, the samples were
boiled for 10 min to inactivate the enzyme, quickly centri-
fuged and 1 L was used for the PCR amplifications. PCR
was performed using AmpliTaq Gould (Perkin Elmer –
Roche, Branchburg, NJ, USA) and the reagents supplied
according to the PCR programme: initial denaturation
(94C, 7 min) followed by 35 cycles of denaturation
(94C, 15 sec), annealing (45–50C, 15 sec) and exten-
sion (72C, 15 sec) whereafter a final elongation step at
72C for 10 min was added followed by cooling at 4C.
All primer sequences and exact PCR conditions are availa-
ble from the authors upon request. DNA sequencing wasPage 2 of 8
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cycle sequencing with AmpliTaq polymerase FS and the
reagents supplied by Applied Biosystems (Foster City, CA,
USA).
MSI-analysis
MSI was determined using the mononucleotide markers
BAT25, BAT26, BAT34C4, BAT40 and the dinucleotide
markers D2S123 and D17S250. All these MSI markers are
among those recommended in the NCI reference panel
for the classification of MSI [19]. All primer sequences are
available from the authors upon request. Fluorescently la-
belled forward primers were used for the PCR reactions:
Tet (green) for BAT25, Fam (blue) for BAT26, BAT34C4
and D2S123 and Hex (yellow) for BAT40 and D17S250.
The PCR products were mixed with formamide and Ge-
neScan 500 TAMRA size standard (Applied Biosystems),
denatured and separated in Performance Optimized Poly-
mer-4 (POP-4™) on a ABI PRISM™ 310 Genetic Analyzer
(Applied Biosystems). The tumors were classified as MSI-
high if at least 2/5 markers displayed MSI, as MSI-low if
instability was present in 1/5 markers and as MSS if none
of the 5 markers showed instability.
CTNNB1 mutations
Exon 3 of the CTNNB1 gene, which codes for -catenin,
was analysed using DNA sequencing and a PCR-based as-
say designed to detect larger deletions of this region. Exon
3 was sequenced using the primers 5'-TGTAAAACGACG-
GCCAGTCGTATTTATAGCTGATTTGA-3' (forward) and
5'-TACTCTTACCAGCTACTTGT-3' (reverse). Genomic de-
letions involving exon 3 were analyzed by PCR amplific-
tion using the primers 5'-CCAGCGTGGACAATGGCTAC-
Table 1: Summary of clinicopathological data
Tumor 
no.
Sex/age Family history 




Pre-op radio-therapy Dukes'/TNM 
stage




1 25/F No m + C/T4N1M0 mo FLV 46
2 31/F No h + C/T3N1M0 mo FLV 84
3 32/M Fa m + D/T4N1M1 mo FLV+OX 0/15
4 32/M No m + B/T3N0M0 mo FLV 33
5 33/M No m + B/T3N0M0 mo - 85
6 37/M No h - B/T3N0M0 mo - 80
7 38/M No m + A/T2N0M0 mo - 61
8 38/M Am h - A/T1N0M0 we - 49
9 39/M Ud l + D/T4N2M1 mu, si - 0/8
10 39/F Am h - A/T2N0M0 mo - 32
11 41/M No h + A/T2N0M0 mu - 35
12 41/M Fa h + B/T3N0M0 mo FLV 34
13 42/M Fa l + C/T3N1M0 mo FLV 27
14 43/F No h + D/T4N2M1 mo FLV 0/20
15 43/M No m + C/T3N1M0 mo FLV 46
16 44/M No m + B/T3N0M0 po - 19
17 44/F Fa m - C/T3N1M0 mu FLV 10/22
18 45/M No m + B/T3N0M0 mo - 71
19 45/M No h + C/T4N1M0 mo FLV 55
20 47/M No m - C/T3N1M0 mo - 28
21 47/F Fa l + C/T3N1M0 mo FLV 24
22 47/M No m - D/T3N0M1 mo FLV 0/40
23 47/F No l + C/T3N2M0 mu, si FLV 11/17
24 48/M No h + D/T4N2M1 mo FLV 0/24
25 49/M No h + D/T4N2M1 mu FLV 0/3
26 49/M Ud h + C/T3N1M0 mo FLV 27/38
27 49/M No h - C/T3N2M0 mo - 62
28 49/M No m + A/T2N0M0 mo - 37
29 49/F No m + A/T2N0M0 mo - 72
30 49/F Fa l + C/T3N1M0 mo - 71
Abbreviations: family history; Am: Amsterdam II criteria fulfilled, Fa: familial, No: no history; Ud:undetermined tumor location; h:high, m:middle, 
l:low differentiation; we:well, mo:moderate, po:poor, mu:mucinous, si:signet ring cell FLV; 5-FU + leucovorinPage 3 of 8
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verse), followed by size separation in acrylamide gels.
KRAS mutations
KRAS was analyzed for point mutations in codons 12, 13
and 61 by sequencing. PCR amplification was performed
in two fragments using the primer pairs K1 (covering co-
dons 12–13) 5'-GGCCTGCTGAAAATGACTGA-3' (for-
ward) and 5'-GTCCTGCACCAGTAATATGC-3' (reverse)
and K2 (covering codon 61) 5'-TTCCTACAGGAAGCAAG-
TAG-3' (forward) and 5'-CACAAAGAAAGCCCTCCCCA-
3' (reverse).
Immunohistochemistry for TP53, -catenin, MLH1 and 
MSH2
Fresh 5-M sections from paraffin embedded tumor
blocks were transferred to glass slides (DAKO ChemMate
capillary gap microscope slides, 75 M, DAKO A/S, Den-
mark). Following deparaffinisation in xylene and rehydra-
tion through graded ethanol, the sections were microwave
treated at 750 W in citrate or EDTA buffer (Table 2) for 15
min to achieve antigen retrieval. Staining was performed
in an automated immunostainer (TechMate™ 500 Plus,
DAKO A/S, Denmark) using the biotin-streptavidin-per-
oxidase procedure with diaminobenzidine as the chro-
mogen. Endogenous peroxidase activity was blocked by
incubation in H2O2. All antibodies used were commer-
cially available mouse monoclonal IgG's (Table 2). After
counterstaining with hematoxylin the slides were dehy-
drated in ascending concentrations of alcohol and mount-
ed. The immunohistochemical staining (Fig. 1) was
independently evaluated by two of the investigators (E.F.
and M.N.). The staining for MLH1 and MSH2 was nuclear
and was classified as present or absent in the tumor tissue,
and retained expression was in all tumors identified in
surrounding normal crypts and in the tumor stroma. Nu-
clear p53 staining was evaluated in 5 high power fields
(HPFs) (x40) and was classified as positive if >5% of the
tumor cell nuclei were stained. Immunohistochemical
staining for -catenin normally results in a membraneous
and/or a weak cytoplasmic staining, whereas a mutation
leading to -catenin stabilization is reflected as an in-
creased cytoplasmic or nuclear staining. We classified the
predominant -catenin staining pattern in 5 HPFs accord-
ing to cellular localization as membraneous, cytoplasmic
or nuclear.
DNA flow cytometry
50-M sections from paraffin embedded tumor tissue
were used for flow cytometric DNA analysis. The nuclear
suspension was stained with propidium iodide for the
DNA quantification in an Ortho-Cytoron Absolute flow
cytometer (Ortho Diagnostics, Raritan, NJ, USA). Up to
20,000 nuclei were analyzed per sample, which created a
histogram profile with 256 channel resolution. Chicken
and trout red blood cells were used as internal controls. A
cell population was defined as a G0/G1 peak with a corre-
sponding G2 peak. Tumors with a single G0/G1 peak were
classified as DNA diploid (DNA-index of 1.0). If more
than one cell population was present the sample was clas-
sified as aneudiploid. The degree of DNA aneuploidy was
expressed as the DNA index (DI) which represents the po-
sition of the aneuploid peak in relation to the diploid ref-
erence cells. ModFitLT 3.0 software from Verity Software
House Inc. (Topsham, ME, USA) was used for the analysis
of the DNA histograms.
Results
The results of the molecular genetic characterization of the
tumors are presented in Table 3. In summary, aneuploidy
was found in 21/30 tumors (7 of which were near-diploid
with a DI of 1.1–1.2) whereas 9 tumors (including the 3
MSI tumors) were diploid. No tumor displayed any muta-
tion involving exon 3 of CTNNB1, but immunohisto-
chemical staining for -catenin revealed a membraneous
staining in 5 tumors, a cytoplasmic staining in 19 tumors
and a nuclear staining for -catenin in 6 tumors. p53 was
immunohistochemically expressed in 18/30 tumors;
strong wide-spread nuclear staining was found in 16 tu-
mors and a weaker staining in >5% of the tumor cells in 2
tumors. KRAS mutations were identified in 6 patients
(20%); all mutations were missense mutations, 5 muta-
Table 2: Antibodies and conditions used for immunohistochemistry
Antibody Clone Company Dilution Buffer
p53 DO-7 DAKO A/S, Glostrup, Denmark 1:300 Citrate
-catenin 14 Transduction laboratories Lexington, 
KY, USA
1:5000 Citrate
MLH1 G168-5 PharMingen, San Diego CA, USA 1:100 EDTA
MSH2 FE-11 Oncogene Research Products, Bos-
ton, MA, USA
1:100 EDTAPage 4 of 8
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no mutation was detected in codon 61. All 6 tumors with
KRAS mutations displayed immunohistochemical p53
protein expression. MSI was found in 3 tumors and the re-
maining 27 tumors were MSS. All 30 tumors displayed
normal expression of MLH1, whereas loss of expression
for MSH2 was detected in 3 tumors. A family history of
colorectal cancer (in 2 patients in combination with en-
dometrial cancer) was reported in 8/28 evaluable patients,
2 of which also fulfilled the Amsterdam II criteria for the
diagnosis of HNPCC.
Discussion
We characterized 30 rectal cancers from patients younger
than 50 years at diagnosis with respect to tumor biologic
phenomena associated with the MSI and the CIN path-
ways for colorectal tumor development. Rectal cancer has
been associated with a higher frequency of aneuploidy,
MSS tumors, mutations in KRAS and TP53 and nuclear ac-
cumulation of -catenin compared to colon cancer, which
probably reflects different preferred pathways in the de-
velopment of these tumor types [3,12,14–18]. Our find-
ings of high frequencies of MSS (27/30) tumors,
aneuploidy (21/30), immunohistochemical p53 expres-
sion (18/30) and increased -catenin expression (25/30)
(Table 3) is in line with previous reports of genetic altera-
tions in rectal cancer, but support such a model for the de-
velopment of rectal cancer also in the majority of young
patients.
Figure 1
Immunohistochemical staining of tumor 10 a) normal nuclear staining for MLH1 in the tumor as well as in stromal tis-
sue, b) loss of nuclear expression of MSH2 in tumor tissue but retained staining in stromal cells, c) nuclear staining for p53, and
d) membraneous and intense cytoplasmic staining for -catenin.
a b
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MSI, which is higher than the 1–2% MSI detected in larger
series of rectal cancers, but lower than the 15% MSI tu-
mors observed among sporadic colorectal cancers. This
finding indicates that the frequency of MSI in young pa-
tients with rectal cancer is considerably lower than the
17–58% MSI tumors and 20–40% HNPCC-causing muta-
tions reported in mixed series of colorectal cancers from
young patients [5–10,14,18]. All three MSI tumors identi-
fied in our study displayed immunohistochemical loss of
MSH2 expression. Whereas immunohistochemical loss of
MLH1 may reflect either a germline mutation or somatic
hypermethylation of the MLH1 promoter, loss of MSH2
expression is almost exclusively caused by a germline mu-
tation of the MSH2 gene [12,19,20]. Thus, hypermethyla-
tion of MLH1 plays a limited role in rectal cancers from
young patients, which is in accordance with an associa-
tion between MLH1 hypermethylation and proximal tu-
mors, older patients and female sex [13]. Consequently,
the finding of MSI in a rectal cancer is, together with a
family history of the disease, a strong indicator of HN-
PCC. Although HNPCC-associated tumors show a pre-
diliction for the proximal colon about 40% of HNPCC-
associated tumors will develop in the distal colon or with-
in the rectum.
Mutations in codons 12 and 13 of KRAS are found in
about 1/3 of colorectal tumors [21,22]. These mutations
develop early in colorectal tumor progression [23]. The
prognostic value of KRAS mutations is somewhat unclear,
but a recent study compiling data from over 3000 patients
with colorectal cancer, did in a multivariate analysis dem-
onstrate a significant impact on survival by the codon 12
glycine  alanine mutation, which is found in about 9%
of the tumors [24]. We identified KRAS mutations in 6/30
rectal cancers (Table 3). All mutations were heterozygous
missense mutations of types that have previously been de-
scribed, and one patient displayed the codon 12 glycine
Table 3: Summary of molecular genetic alterations
Tumor no. DI MSI MSH2 MLH1 B-cat. TP53 KRAS mut.
1 2.1 - + + C - -
2 1.1 - + + C - -
3 1.4 - + + C + 12, GGT->GAT
4 4.5 - + + C + 12, GGT->GTT
5 2.0 - + + C + -
6 1.4 - + + C + 12, GGT->TGT
7 1.7 - + + C - -
8 1.0 + - + M - -
9 1.5 - + + M + -
10 1.0 + - + C + 13, GGC->GAC
11 1.0 - + + C - -
12 1.0 + - + N - -
13 1.6 - + + C - -
14 1.0 - + + N + -
15 1.0 - + + C + -
16 1.0 - + + M + -
17 1.0 - + + M - -
18 1.1 - + + C + -
19 1.1 - + + C + -
20 1.3 - + + N - -
21 1.8 - + + C + -
22 1.3 - + + N - -
23 1.2 - + + C - -
24 1.7 - + + N - -
25 1.0 - + + M + -
26 2.0 - + + N + -
27 1.2 - + + C + 12, GGT->GAT
28 1.6 - + + C + -
29 1.2 - + + C + 12, GGT->AGT
30 1.1 - + + C + -
Abbreviations: DI: DNA index C:cytoplasmic, M:membraneous, N:nuclearPage 6 of 8
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has been found in distal tumors and an inverse relation-
ship between MSI and alterations of KRAS and TP53 mu-
tations has been described [22], a finding that is
supported by our data with KRAS mutations in 6/30 tu-
mors and nuclear expression of p53 in 18/30 rectal can-
cers.
-catenin is involved in cell-cell adhesion as well as in sig-
nal transduction. Free -catenin is bound to the adenom-
atosis polyposis coli (APC) protein and to glycogen
synthase kinase 3B (GSK-3B), which phosphorylate ser-
ine/threonine residues in -catenin and thereby destabi-
lizes the protein, which is degraded by the ubiquitin-
proteasome pathway. Mutations of APC or of the regula-
tory domain of CTNNB1 has been demonstrated in color-
ectal cancer and lead to stabilization and cytoplasmic
accumulation of free -catenin [25,26]. Increased cyto-
plasmic levels of -catenin allows the protein to enter the
nucleus where it promotes transcriptional activation
through the TCF/LEF transcription factors. We found no
mutations in the regulatory domain (exon 3) of the
CTNNB1 gene, but immunohistochemitry for -catenin
revealed an increased cytoplasmic expression or a nuclear
accumulation in 25/30 tumors. Nuclear accumulation of
-catenin has been reported to occur at a higher frequency
in rectal cancer than in colon cancer, whereas mutations
affecting the CTNNB1 gene, have been reported to occur
at a higher frequency in MMR-deficient tumors [26,27].
Conclusions
We conclude that rectal cancer, also when developing in
young patients, is frequently associated with DNA-aneu-
ploidy, increased expression of p53 and -catenin, where-
as MSI and mutations in KRAS occur at a low frequency.
In this study only 10% of the rectal cancers from young
patients were MSI-high, but all of these tumors showed
loss of expression for MSH2, which suggests an underly-
ing HNPCC-causing mutation. Thus, other mechanisms
than defective MMR and HNPCC probably cause rectal
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